Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immuni...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cells in myeloma: are they as promising as we think?
With the impressive results from initial trials using CAR T-cells, excitement surrounding this modality as a curative therapy was high. However, as explained bhere y Faith Davies MD, MRCP, MRCPath, FR...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Promising new therapies for multiple myeloma
In this interview, Faith Davies, MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, discusses the various drugs that are either approved or currently in trials for multiple myel...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Earlier Diagnosis for Smoldering Multiple Myeloma or Monoclonal Gammopathy of Unknown Significance | At Risk of Progressing to Light-chain Amyloidosis
Ray Comenzo, MD, Tufts Medical Center, explains Earlier Diagnosis for SMM or MGUS | At Risk of Progressing to Light-chain Amyloidosis at ASCO 2018
Author: Annual-Meeting
Added: 06/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Many Drugs Being Looked at for Multiple Myeloma CD38 and Venetoclax
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., talks about Many Drugs Being Looked at for Multiple Myeloma CD38 and Venetoclax at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel Endpoints in MRD in Multiple Myeloma Novel Drugs Targeting BiTE Platform
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Novel Endpoints in MRD in Multiple Myeloma Novel Drugs Targeting BiTE Platform at ASCO 2018
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Data from ARROW Trial for Multiple Myeloma Progression-free survival with KYPROLIS
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., discusses Data from ARROW Trial for Multiple Myeloma Progression-free survival with KYPROLIS at ASCO 2018.<br />
Author: Annual-Meeting
Added: 06/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Paul Richardson, MD - Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT
Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT (Source: PeerView CME/CE Audio Podcast - Immunology)
Source: PeerView CME/CE Audio Podcast - Immunology - May 22, 2018 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities
Ruben Niesvizky, MD, explains Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity
Paul G. Richardson, MD, explains One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity
Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 8, 2018 Category: Cancer & Oncology Source Type: podcasts
The challenges of treating plasma cell leukemia
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the early symptoms of plasma cell myeloma. Patients with PCL tend to present with aggres...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmar...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Can genetic abnormalities be targeted in MM?
New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, covers what is known about Monoc...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Making sense of the many treatment options for relapsed MM: cost-effectiveness
There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs between countries and locations. In this interview, Jean-Luc Har...
Author: VJHemOnc
Added: 05/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 4, 2018 Category: Cancer & Oncology Source Type: podcasts
